Long-Hung Pham

Long-Hung Pham

Auto-generated profile, based on publicly available information

Long-Hung Pham

Imperial College London

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Natural Products and Bioprospecting
Verified
Journal Article
Open access
PDF file
TLThua-Phong Lam
Thua-Phong Lam
NTNgoc-Vi Nguyen Tran
Ngoc-Vi Nguyen Tran
LPLong-Hung Dinh Pham
Long-Hung Dinh Pham
NLNghia Vo-Trong Lai
Nghia Vo-Trong Lai
BDBao-Tran Ngoc Dang
Bao-Tran Ngoc Dang
TTThanh Dao Tran
Thanh Dao Tran
Diabetes mellitus remains a major global health issue, and great attention is directed at natural therapeutics. This systematic review aimed to assess the potential of flavonoids as antidiabetic agents by investigating their inhibitory effects on α-glucosidase and α-amylase, two key enzymes involved in starch digestion. Six scientific databases (PubMed, Virtual Health Library, EMBASE, SCOPUS, Web of Science, and WHO Global Index Medicus) were searched until August 21, 2022, for in vitro studies reporting IC50 values of purified flavonoids on α-amylase and α-glucosidase, along with corresponding data for acarbose as a positive control. A total of 339 eligible articles were analyzed, resulting in the retrieval of 1643 flavonoid structures. These structures were rigorously standardized and curated, yielding 974 unique compounds, among which 177 flavonoids exhibited inhibition of both α-glucosidase and α-amylase are presented. Quality assessment utilizing a modified CONSORT checklist and structure–activity relationship (SAR) analysis were performed, revealing crucial features for the simultaneous inhibition of flavonoids against both enzymes. Moreover, the review also addressed several limitations in the current research landscape and proposed potential solutions. The curated datasets are available online at https://github.com/MedChemUMP/FDIGA. Graphical Abstract

26 February 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
HMHugo MacDermott-Opeskin
Hugo MacDermott-Opeskin
JSJenke Scheen
Jenke Scheen
CWCas Wognum
Cas Wognum
JHJoshua T. Horton
Joshua T. Horton
DWDevany West
Devany West
JCJohn Chodera
John Chodera

22 December 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
LPLong-Hung Dinh Pham
Long-Hung Dinh Pham
MLMinh-Tri Le
Minh-Tri Le
Khac-Minh ThaiKhac-Minh Thai
Khac-Minh Thai

11 September 2024 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
NKNguyen Tan Khanh
Nguyen Tan Khanh
MTManh Hung Tran
Manh Hung Tran
Truong Tan TrungTruong Tan Trung
Truong Tan Trung
LPLong-Hung Dinh Pham
Long-Hung Dinh Pham
PTPhu Chi Hieu Truong
Phu Chi Hieu Truong
PPPhu Tran Vinh Pham
Phu Tran Vinh Pham

6 January 2026 in ChemRxiv
Verified
Preprint
Open access
PDF file
HMHugo MacDermott-Opeskin
Hugo MacDermott-Opeskin
JSJenke Scheen
Jenke Scheen
CWCas Wognum
Cas Wognum
JHJoshua T. Horton
Joshua T. Horton
DWDevany West
Devany West
JCJohn Chodera
John Chodera
Computational blind challenges offer critical, unbiased assessment opportunities to assess and accelerate scientific progress, as demonstrated by a breadth of breakthroughs over the last decade. We report the outcomes and key insights from an open science community blind challenge focused on computational methods in drug discovery, using lead optimization data from the AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium’s pan-coronavirus antiviral discovery program, in partnership with Polaris and the OpenADMET project. This collaborative initiative invited global participants from both academia and industry to develop and apply computational methods to predict the biochemical potency and crystallographic ligand poses of small molecules against key coronavirus targets, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) main protease (Mpro), as well as multiple ADMET assay endpoints, using previously undisclosed comprehensive experimental drug discovery datasets as benchmarks. By evaluating submissions across multiple tasks and compounds, we established performance leaderboards and conducted meta-analyses to assess methodological strengths, common pitfalls, and areas for improvement. This analysis provides a foundation for best practices in real-world machine learning evaluation, grounded in community-driven benchmarking. We also highlight how next-generation platforms, such as Polaris, enable rigorous challenge design, embedded evaluation frameworks, and broad community engagement. This paper reports the collective findings of the challenge, offering a high-level overview of the data, evaluation infrastructure, and top- performing strategies. We further provide context and support for the accompanying papers authored by the challenge participants in this special issue, which explore individual approaches in greater depth. Together, these contributions aim to advance reproducible, trustworthy, and high-impact computational methods in drug discovery, and to explore best practices and pitfalls in future blind challenge design and execution, including planned initiatives for the OpenADMET project.